

**Table 13      Proportion of Subjects Having Spironolactone Titrations over Time (ITT Population)**

	Spironolactone + Placebo (N=148)		Spironolactone + Patiromer (N=147)	
	Up n/N (%)	Down n/N (%)	Up n/N (%)	Down n/N (%)
≤Week 1	0/148 (0.0%)	2/148 (1.4%)	0/147 (0.0%)	1/147 (0.7%)
>Week 1 and ≤Week 2	0/144 (0.0%)	0/144 (0.0%)	0/144 (0.0%)	2/144 (1.4%)
>Week 2 and ≤Week 3	77/136 (56.6%)	2/136 (1.5%)	88/138 (63.8%)	2/138 (1.4%)
>Week 3 and ≤Week 4	21/131 (16.0%)	5/131 (3.8%)	27/136 (19.9%)	6/136 (4.4%)
>Week 4 and ≤Week 6	11/127 (8.7%)	7/127 (5.5%)	10/134 (7.5%)	8/134 (6.0%)
>Week 6 and ≤Week 8	6/117 (5.1%)	8/117 (6.8%)	6/133 (4.5%)	5/133 (3.8%)
>Week 8 and ≤Week 10	7/105 (6.7%)	7/105 (6.7%)	6/128 (4.7%)	4/128 (3.1%)
>Week 10 and ≤Week 12	0/23 (0.0%)	1/23 (4.3%)	1/21 (4.8%)	3/21 (14.3%)

Notes: Denominators at a time interval are the number of subjects prescribed with doses by Investigators.  
ITT=Intent-to-treat.